Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly

Paying $675m Upfront For Rights To RET Inhibitor

 
• By Kevin Grogan
Gears_Sunlight
Roche looks a good fit for marketing pralsetinib • Source: Shutterstock

More from Deals

More from Business